Recent share performance and business context

ACADIA Pharmaceuticals (ACAD) has seen mixed share performance recently, with a 2.5% decline over the past day, a 3.6% gain over the past week, and weaker moves over the past month and past 3 months.

At a last close of US$21.47 and a market value of about US$3.8b, the company generates US$1,071.5m in revenue and US$391.0m in net income from its neurology focused medicines and pipeline programs.

ACADIA’s recent share price performance is mixed, with short term weakness including a 30 day share price return of 12.7% and 90 day return of 22.3%. However, a 1 year total shareholder return of 24.9% and 3 year total shareholder return of 14.8% highlight that longer term holders have still seen gains.

If this kind of move in a neurology focused name has your attention, it could be a good moment to scan the wider healthcare AI opportunity set through our stock screener, starting with 36 healthcare AI stocks.

With ACADIA trading at US$21.47, reporting US$1.1b in revenue and US$391.0m in net income, the key question is whether current valuations leave room for further upside or if the market already reflects expectations for future growth.

Most Popular Narrative: 25.3% Undervalued

ACADIA’s most followed narrative pegs fair value at $28.75 per share, compared with the last close at $21.47. This frames the stock as materially undervalued.

ACADIA’s valuation reflects market caution. Investors are pricing in uncertainty around pipeline expansion and long-term growth durability. Yet that same caution creates optionality. Any evidence of sustained diversification or improved operating leverage could shift sentiment quickly.

There is a clear set of revenue growth and margin assumptions sitting behind that $28.75 fair value, plus a profit multiple that leans on specialty pharma characteristics rather than broad biotech averages. It is worth understanding which numbers are doing the heavy lifting and how sensitive that narrative is to execution on new indications and cash generation.

Result: Fair Value of $28.75 (UNDERVALUED)

However, this hinges on clinical execution and regulatory outcomes. Any trial setback or approval delay could quickly challenge the current undervalued story.

Next Steps

With sentiment split between caution and optimism around ACADIA, it helps to inspect the numbers yourself and move quickly while the story is still forming. To understand what is driving the current optimism, take a closer look at the 4 key rewards.

Looking for more investment ideas?

If ACADIA has you thinking about what else might be worth attention, this is a good moment to widen your watchlist using focused stock screeners.

• Target income first by checking out stable names offering higher yields through the 12 dividend fortresses.
• Hunt for potential value opportunities that combine quality fundamentals with attractive pricing using the 61 high quality undervalued stocks.
• Prioritize resilience by scanning companies that pair stronger balance sheets with solid fundamentals via the solid balance sheet and fundamentals stocks screener (39 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.